Atea Pharmaceuticals (AVIR) Income from Continuing Operations (2019 - 2026)

Atea Pharmaceuticals' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 45440000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 32.59% year-over-year to 45440000.0; the TTM figure through Mar 2026 stood at 169517000.0 (down 21.53% YoY), while the FY2025 annual figure was 158349000.0, up 5.96% from the prior year.
• Income from Continuing Operations was 45440000.0 for Q1 2026 at Atea Pharmaceuticals, down from 44867000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 8066000.0 in Q3 2022 to a low of 63169000.0 in Q1 2024.
• Historically, Income from Continuing Operations has averaged 36708176.47 across 5 years, with a median of 35467000.0 in 2023.
• Biggest YoY gain for Income from Continuing Operations was 71.39% in 2022; the steepest drop was 2136.06% in 2022.
• A 5-year view of Income from Continuing Operations shows it stood at 34431000.0 in 2022, then retreated by 13.75% to 39164000.0 in 2023, then advanced by 14.35% to 33543000.0 in 2024, then slumped by 33.76% to 44867000.0 in 2025, then decreased by 1.28% to 45440000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 45440000.0 (Q1 2026), 44867000.0 (Q4 2025), and 42049000.0 (Q3 2025), per Business Quant data.